We are live on ! Find out more
NTLA icon

Intellia Therapeutics
NTLA

165 hedge funds and large institutions have $1.12B invested in Intellia Therapeutics in 2020 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 69 increasing their positions, 33 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

109% more repeat investments, than reductions

Existing positions increased: 69 | Existing positions reduced: 33

101% more call options, than puts

Call options by funds: $3.84M | Put options by funds: $1.92M

1.32% more ownership

Funds ownership: 94.85% → 96.17% (+1.3%)

4% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 25

1% more funds holding

Funds holding: 164 → 165 (+1)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

1% less capital invested

Capital invested by funds: $1.13B → $1.12B (-$11.2M)

Holders
165
Holders Change
+1
Holders Change %
+0.61%
% of All Funds
3.33%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
26
Increased
69
Reduced
33
Closed
25
Calls
$3.84M
Puts
$1.92M
Net Calls
+$1.93M
Net Calls Change
-$1.26M

Top Buyers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
+$15.4M
2
BlackRock
BlackRock
New York
+$12.4M
3
Goldman Sachs
Goldman Sachs
New York
+$8.64M
4
Morgan Stanley
Morgan Stanley
New York
+$8.48M
5
Millennium Management
Millennium Management
New York
+$6.85M

Top Sellers

Rank Fund Capital Flow
1
APM
Avidity Partners Management
Texas
-$8.79M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$4.79M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
-$4.54M
4
O
OrbiMed
New York
-$2.88M
5
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group
Japan
-$2.77M
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of New York Mellon
26
Bank of New York Mellon
New York
$3.74M +$28.4K +1,360 +0.7%
D.E. Shaw & Co
27
D.E. Shaw & Co
New York
$3.42M -$469K -22,492 -12%
Susquehanna International Group
28
Susquehanna International Group
Pennsylvania
$2.89M +$1.97M +94,461 +186%
CS
29
Credit Suisse
Switzerland
$2.55M +$432K +20,737 +19%
Royal Bank of Canada
30
Royal Bank of Canada
Ontario, Canada
$2.5M -$44.2K -2,121 -2%
BBA
31
Baker Bros. Advisors
New York
$2.43M -$131K -6,300 -5%
Federated Hermes
32
Federated Hermes
Pennsylvania
$2.36M +$883K +42,328 +55%
California Public Employees Retirement System
33
California Public Employees Retirement System
California
$2.25M +$515K +24,682 +28%
ROTUOC
34
Regents of the University of California
California
$2.21M – – –
CIA
35
Capital Impact Advisors
Massachusetts
$2.19M +$2.29M +110,000 New
Swiss National Bank
36
Swiss National Bank
Switzerland
$2.05M +$31.3K +1,500 +1%
RhumbLine Advisers
37
RhumbLine Advisers
Massachusetts
$1.95M +$129K +6,188 +7%
Legal & General Group
38
Legal & General Group
United Kingdom
$1.86M +$730K +35,020 +60%
PP
39
PDT Partners
New York
$1.66M -$389K -18,634 -18%
Rafferty Asset Management
40
Rafferty Asset Management
New York
$1.62M +$1.2M +57,319 +235%
California State Teachers Retirement System (CalSTRS)
41
California State Teachers Retirement System (CalSTRS)
California
$1.51M +$203K +9,749 +15%
UBS Group
42
UBS Group
Switzerland
$1.5M -$213K -10,204 -12%
GIM
43
Granahan Investment Management
Massachusetts
$1.47M -$47.4K -2,271 -3%
Squarepoint
44
Squarepoint
New York
$1.46M +$403K +19,350 +36%
State of Wisconsin Investment Board
45
State of Wisconsin Investment Board
Wisconsin
$1.4M +$196K +9,400 +15%
SCM
46
Shelton Capital Management
Colorado
$1.36M – – –
EWM
47
Elmwood Wealth Management
California
$1.35M – – –
Wells Fargo
48
Wells Fargo
California
$1.32M -$913K -43,787 -40%
UBS AM
49
UBS AM
Illinois
$1.29M +$107K +5,136 +9%
PIM
50
Platinum Investment Management
Australia
$1.29M -$390K -18,706 -22%
1
2
3 4 5

NTLA Hedge Fund Activity: Q3 2020 in Review

165 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Intellia Therapeutics (NTLA) for Q3 2020, worth a combined $1.12B — down 1% from $1.13B a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new NTLA positions and 25 closed out — a net gain of 1 holder — while 69 added to existing stakes and 33 trimmed.

The largest buyer was State Street, adding an estimated $15.4M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $8.79M sold.

  • 165 institutional investors held Intellia Therapeutics (NTLA) as of Q3 2020, up from 164 in Q2 2020.
  • Funds reported $1.12B of Intellia Therapeutics stock for Q3 2020, down 1% quarter-over-quarter.
  • 26 funds opened new Intellia Therapeutics positions in Q3 2020 and 25 closed out, a net change of +1 holder.
  • The largest Intellia Therapeutics buyer in Q3 2020 was State Street, an estimated $15.4M added.
  • The largest Intellia Therapeutics seller in Q3 2020 was Avidity Partners Management, an estimated $8.79M sold.

Based on aggregated 13F filings for Q3 2020.